GSK’s asthma push continues as drug succeeds in Phase 3 trials
A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced.
A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced.
Instructions for Authors | JAMA | JAMA Network Instructions for Authors Contact Monica Mungle for help if edits are needed to the top section. Open…
Pule and colleagues screened a library of Fas-TNFR chimeras in human T cells identifying Fas-CD40 as the optimal chimera for converting the FasL-inducing death response into…
Kaiser Permanente made waves when created a new, sprawling entity of nonprofit hospitals and doctors with Geisinger as its first takeover. Which health system is…
To fight an existential-scale threat like antibiotic resistance, the world needs all the brainpower it can muster. Just the opposite is happening, with an ever-diminishing…
People with cystic fibrosis are particularly susceptible to chest infection. It’s important to find treatments for these infections and a Cochrane Review from Cochrane Cystic…
Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused…
The healthcare data company, thrown off the Nasdaq stock exchange for failing to file financial reports, said it’s exploring ways to “maximize shareholder value.”
Agios said Monday that its beta-thalassemia drug achieved the primary goal of a Phase 3 trial, reducing the need for blood transfusions.
In this study, Mehta et al. dissect the roles of Atoh7 cis-regulatory elements during retinogenesis. They demonstrate that deleting the enhancer landscape upstream of Atoh7 phenocopies…
Diabetes, Obesity & Metabolism is an interdisciplinary journal for clinical & experimental pharmacology and therapeutics relating to metabolic & endocrine disease.